GlassScriptPhysician profile
Harold K Cathcart
NPI 1104815935
$4,820.84
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2021: $34.66 · 2022: $1,138 · 2023: $910 · 2024: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,492.29 | 2019 | |
| Lilly USA, LLC | $805.49 | 2022-2024 | Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $405.82 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $392.30 | 2019-2024 | Evenity, Prolia, Tavneos |
| Medtronic, INC. | $286.74 | 2021-2023 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Novo Nordisk INC | $266.00 | 2022-2024 | Wegovy, Ozempic, Sogroya |
| Bayer Healthcare Pharmaceuticals INC. | $142.98 | 2023-2024 | |
| Corcept Therapeutics | $136.23 | 2023-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $118.40 | 2019 | |
| Abbott Laboratories | $109.07 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $90.65 | 2022-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.39 | 2023-2024 | Jardiance, Cyltezo |
| Mannkind Corporation | $70.35 | 2024 | |
| Recordati_rare_diseases_inc. | $55.05 | 2022-2024 | Isturisa, Signifor Lar |
| Nevro Corp. | $51.28 | 2022-2023 | Senza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $45.91 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Genentech USA, INC. | $33.39 | 2022-2024 | Actemra |
| Chiesi USA, INC. | $31.96 | 2024 | Mycapssa |
| Dexcom, INC. | $29.63 | 2022-2023 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $22.16 | 2021 | |
| Calliditas Therapeutics US INC. | $22.12 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.06 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.97 | 2023 | Strensiq |
| Janssen Biotech, INC. | $18.19 | 2023 | Tremfya |
| Sanofi-Aventis U.S. LLC | $17.39 | 2022 | |
| Eusa Pharma (US) LLC | $17.08 | 2022 | |
| Radius Health, INC. | $14.29 | 2022 | |
| Biomarin Pharmaceutical INC. | $13.94 | 2023 | Palynziq |
| Amryt Pharma Holdings LTD | $13.71 | 2023 | Mycapssa |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Cathcart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.